Solid prices $125M IPO, discloses partial clinical hold

Solid Biosciences Inc. (NASDAQ:SLDB) raised $125 million after market hours Thursday through the sale of 7.8 million shares at $16 in a downsized IPO underwritten by J.P. Morgan, Goldman Sachs, Leerink, Nomura and Chardan. The IPO price values the gene therapy company at $546.4 million. On Wednesday, Solid amended its proposed IPO to sell 7 million shares at $18-$19 (see BioCentury Extra, Jan. 24).

Also on Thursday and just before pricing the IPO, Solid disclosed in an SEC filing that FDA placed a partial clinical hold in November on the ascending-dose adaptive Phase I/II IGNITE DMD study of SGT-001 to treat Duchenne muscular dystrophy (DMD)...